What Organon & Co. does.

Organon & Co. (“Organon,” the “Company,” “we,” “our,” or “us”) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across women’s health and general medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 countries and territories. We sell these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers such as health maintenance organizations, pharmacy benefit managers and other institutions. We operate six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom (“UK”). Unless otherwise indicated, trademarks appearing in italics throughout this document are trademarks of, or are used under license by, the Organon group of companies.

• Women’s Health : Our women’s health portfolio of products is sold by prescription primarily in two therapeutic areas: contraception, with key brands such as Nexplanon® (etonogestrel implant) (sold as Implanon NXT ™ in some countries outside the United States) and NuvaRing® (etonogestrel / ethinyl estradiol vaginal ring); and fertility, with key brands such as Follistim AQ® (follitropin beta injection) (marketed in most countries outside the United States as Puregon ™). Nexplanon is a long-acting reversible contraceptive in a class recognized as one of the most effective types of hormonal contraception available to patients with a low long-term average cost. Our other women’s health products include the Jada ® System, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. In January 2026, we divested the Jada System to Laborie Medical Technologies Corporation (“Laborie”).

Revenue and profit, by fiscal year.

More on OGN.

• Organon & Co. summary
• Organon & Co. financial statements
• Organon & Co. key metrics
• Organon & Co. health scores and style box
• Organon & Co. earnings
• Organon & Co. dividends
• Organon & Co. valuation
• Organon & Co. ownership and insiders
• Organon & Co. peers

Figures from Organon & Co.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.